Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational

Genetic Study of Schizophrenia

NCT00001486
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
4,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more
Terminated Not applicable Interventional Results available

Boost rTMS for Auditory Verbal Hallucinations

NCT03544333
Conditions
Schizophrenia, Auditory Hallucination
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Schizophrenia and Related Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Columbia University
Other
Eligibility
22 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
45
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 29 more
Terminated Not applicable Interventional Results available

The Use of Transcranial Electrical Stimulation for Hallucinations

NCT02715765
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation, Transcranial Random Noise Stimulation, Transcranial Sham Stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Conditions
Schizophrenia
Interventions
Intervention Active tDCS
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 3 Interventional Results available

Pain Medicine for Wound Care Procedures

NCT00701909
Conditions
Wound Care, Pain Intensity, Hyperalgesia, Nausea, Vomiting, Hallucinations
Interventions
Morphine plus Ketamine, Morphine plus Saline (placebo)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Schizophrenia and Related Disorders
Interventions
Active rTMS stimulation, Sham rTMS stimulation
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational

Perception in Parkinson's Disease

NCT05483036
Conditions
Parkinson's Disease, Perception, Visual Hallucination
Interventions
Not listed
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years to 110 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
Magstim Rapid-2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Impact of VVV Group for Veterans With SMI

NCT05562674
Conditions
Psychotic Disorders, Veterans
Interventions
Veteran Voices and Visions
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Schizophrenia
Interventions
AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • Rockville, Maryland
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Audio Visual Hallucinations, Neurofeedback, Schizophrenia, Superior Temporal Gyrus
Interventions
rt-fMRI neurofeedback
Other
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Brockton, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Brain Stimulation, Clinical Symptoms and Cognition

NCT05053451
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Terminated Not applicable Interventional Results available

Auditory Control Enhancement (ACE) in Schizophrenia

NCT06155695
Conditions
Auditory Hallucinations
Interventions
Transcranial Direct Current Stimulation (tDCS), Auditory Cognitive Control Training (ACCT)
Device · Behavioral
Lead sponsor
Brian A Coffman, PhD
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 91 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Doral, Florida • Miami, Florida
Conditions
Auditory Hallucinations, Schizophrenia
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Lewy Body Dementia, Visual Hallucinations
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Fountain Valley, California • Boca Raton, Florida • Orlando, Florida + 7 more
Conditions
Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
Interventions
Observation of minor phenomena
Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, New York
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more